Understanding Safety, Amyloid-Related Imaging Abnormalities With Lecanemab: Sharon Cohen, MD, FRCPC
September 30th 2022The neurologist and assistant professor at the University of Toronto discussed the real, but tepid significance of amyloid-related imaging abnormalities seen from lecanemab in early-stage Alzheimer disease. [WATCH TIME: 3 minutes]
Assessing Lecanemab’s Effect in Early Alzheimer Disease: Sharon Cohen, MD, FRCPC
September 28th 2022The neurologist and assistant professor at the University of Toronto provided insight on positive topline findings from the phase 3 Clarity AD study of lecanemab in early Alzheimer disease. [WATCH TIME: 4 minutes]
New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD
September 27th 2022New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the new and future treatments for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]
AUPN Leadership Minute Episode 26: Creating a Formal Junior Faculty Development Plan
September 26th 2022Episode 26 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Larry B. Goldstein, MD, of University of Kentucky Medical Center. [WATCH TIME: 8 minutes]
Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin
September 24th 2022The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]
Recommendations for Treating Epilepsy in the Clinical Space: Christopher Elder, MD
September 20th 2022The clinical assistant professor of neurology in the Comprehensive Epilepsy Center at NYU Langone Health gives recommendations for clinical care on prescribed antiseizure medication and RNA therapy. [WATCH TIME: 5 minutes]
Human Endogenous Retroviruses and Their Role in ALS: Avindra Nath, MD
September 19th 2022The clinical director of the National Institute of Neurological Disorders and Stroke provided context on two recent papers that highlight a reactivation of HERV-K virus in the development of amyotrophic lateral sclerosis. [WATCH TIME: 5 minutes]
State of Insomnia Care and Current Effective Treatment Strategies: Ashgan Elshinawy, DO
September 18th 2022The pulmonologist at Penn Medicine provided an evaluation on whether patients with insomnia receive optimal care, and which treatments have proven to be most effective. [WATCH TIME: 3 minutes]
Clinical Presentation of NMOSD and Overcoming Barriers to Access to Care
September 16th 2022Mirla Avila, MD; Michael Levy, MD, PhD; and Mitzi Williams, MD, share the clinical presentation and progression of NMOSD among various racial and ethnic groups and highlight the effects of socioeconomic disparities and personal barriers on access to proper care.
The Potential and Limitations of AI Algorithms in Sleep Care: Anuja Bandyopadhyay, MD
September 15th 2022The assistant professor of clinical pediatrics at Indiana University School of Medicine, and the chair of the AASM’s Artificial Intelligence in Sleep Medicine Committee, spoke about the ability of AI algorithms as tools in clinical care. [WATCH TIME: 3 minutes]
Transitioning Sleep Schedules for School in Pediatric Patients: Carol Rosen, MD
September 15th 2022The professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins. [WATCH TIME: 3 minutes]
The Future of Clinical Care with New Antiseizure Medication: Christopher Elder, MD
September 14th 2022An overview of the shifting landscape of antiseizure medication and various neurostimulation devices is shared by the clinical assistant professor of neurology in the Comprehensive Epilepsy Center at NYU Langone Health. [WATCH TIME: 5 minutes]
Future Implications, Outlook of New CDC Developmental Milestone Guidelines: Paul Lipkin, MD
September 13th 2022The director of medical outpatient services at the Kennedy Krieger Institute discussed the long-term effects of the updated developmental milestone guidelines and the need to judge children based on the 75th percentile. [WATCH TIME: 7 minutes]